Professor, Department of Obstetrics and Gynaecology ; Deputy Director, Prenatal Genetic Diagnosis Centre, CUHK; Director, Pre-implantation Genetic Diagnosis Laboratory, CUHK
BIOGRAPHY
Event Date & Time
Date: April 22, 2021
Time: 10:00am (CEST), 4:00pm (CST)
Abstract
Advancements in technologies have revolutionized the genetic landscape. Chromosomal microarray analysis (CMA) becomes a proven method and is implemented to detect gains and losses of DNA and absence of heterozygosity across the genome. Next-generation sequencing technologies have brought opportunities and challenges to genetic testing, its prenatal application is an emerging field. We describe our experience using FetalChip, a CMA for prenatal research developed in our laboratory and describe the role of CMA in the era of genome sequencing.
Learning Objectives
- The role of chromosomal microarray analysis (CMA) in prenatal genetic clinical research.
- CMA is a well-established and proven technology to identify pathogenic CNVs
- The utility of genome sequencing
For Research Use Only. Not for use in diagnostic procedures.
Webinars will be available for unlimited on-demand viewing after live event.
You May Also Like
DEC 05, 2025 | 1:00 PM
C.E. CREDITS
Explore the evolution, methods, and limitations of mixing studies in detecting factor deficiencies and lupus anticoagulants in coagulation testing....
DEC 09, 2025 | 10:00 AM
Antibody-drug conjugates (ADCs) are transforming oncology by combining the precision of monoclonal antibodies with the potency of cytotoxic drugs. Yet, developing effective ADCs requires ove...
DEC 09, 2025 | 10:00 AM
Ensuring quality and compliance is at the core of every successful clinical laboratory. This webinar brings together CAP expert Daniel and Christie, QA leader from Burning Rock, to explore t...
DEC 10, 2025 | 2:00 PM
Colorectal cancer (CRC) is the second-leading cause of cancer-related deaths in Europe and the U.S.—yet when detected early, the 5-year survival rate jumps to 91% . While colonoscopy r...
DEC 10, 2025 | 8:00 AM
Mass spectrometry (MS)-based proteomic biomarker discovery pipeline commonly begins with large-scale profiling techniques detecting thousands of candidate biomarkers. Efficiently triaging th...
DEC 10, 2025 | 9:00 AM
BACKGROUND . Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid neoplasms with variable clinical outcomes and an increased risk of progression to Acute Myeloid Leukemia (AM...
Loading Comments...